Harvard-Brigham/Anversa $10M FCA settlement (April 2017) — 31 retractions

In April 2017, Harvard and Brigham and Women's Hospital paid $10 million in a False Claims Act settlement on claims related to the Anversa cardiac stem cell research program. The settlement followed (and preceded) 31 papers recommended for retraction in October 2018 (S-0064).

The case prices the FCA mechanism applied to a long-running fraud-pattern preceded by an extensive retraction cascade. The 31 retractions were themselves a downstream consequence of the misconduct that triggered the FCA action — exactly the pattern Stern et al. 2014 (E-0036) measured at sectoral scale.

For M-0003 Term D, the case provides a lower-anchor on the institutional-tail-risk range. Harvard and BWH are among the most prestigious biomedical institutions in the world; the $10M settlement is not a marginal action but a substantial one against a defendant with significant resources and reputational stake.

The architectural reading: even without architectural FCA extension, the precedent stack establishes that FCA settlements for research-data-related claims at major U.S. universities are routine, not exceptional, on the order of $10M-$100M+ per institutional event. The architectural-extension scenario would land on this established precedent.